Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01196871
Recruitment Status : Completed
First Posted : September 9, 2010
Last Update Posted : January 27, 2014
Information provided by (Responsible Party):
Amicus Therapeutics

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : June 2012
  Study Completion Date : October 2012
  Certification/Extension First Submitted : July 18, 2013

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 January 9, 2018 February 14, 2018